Ivabradine Dosing Regimen
The recommended starting dose of ivabradine is 5 mg twice daily with food for adults under 75 years of age, or 2.5 mg twice daily for patients ≥75 years or those with conduction defects, with titration every 2 weeks based on heart rate to a maximum dose of 7.5 mg twice daily. 1
Starting Dose
The initial dose depends on patient age and cardiac conduction status:
- Age <75 years: Start 5 mg twice daily with food 2, 1
- Age ≥75 years: Start 2.5 mg twice daily with food 2
- Conduction defects or risk of hemodynamic compromise from bradycardia: Start 2.5 mg twice daily 1
All doses should be administered with food to optimize absorption.
Titration Protocol
Assess heart rate after 2 weeks and adjust dose according to the following algorithm 2, 1:
- Heart rate >60 bpm: Increase dose by 2.5 mg twice daily (up to maximum 7.5 mg twice daily)
- Heart rate 50-60 bpm: Maintain current dose and monitor
- Heart rate <50 bpm or symptomatic bradycardia: Decrease dose by 2.5 mg twice daily; if already on 2.5 mg twice daily, discontinue therapy
Continue monitoring heart rate regularly and adjust dose as needed based on resting heart rate and tolerability 2.
Maximum Dose
The maximum dose is 7.5 mg twice daily 2, 3, 1. This represents the target dose demonstrated in clinical trials, where the mean achieved dose was 12.8 mg total daily (approximately 6.4 mg twice daily) 3.
Critical Prerequisites Before Initiation
Before starting ivabradine, verify the following 2:
- Beta-blockers optimized: Patient must be on maximally tolerated doses of beta-blockers (or have contraindication to beta-blocker use)
- Sinus rhythm confirmed: Ivabradine is only effective in sinus rhythm
- Heart rate ≥70 bpm: This is the threshold for benefit in heart failure with reduced ejection fraction 4
Common Pitfalls to Avoid
Do not use ivabradine in patients with 1:
- Acute decompensated heart failure
- Atrial fibrillation (regularly monitor for development of AF, as ivabradine increases AF risk to 5.0% per patient-year) 1
- Pacemaker dependence
- Severe hepatic impairment 4
- Concomitant strong CYP3A4 inhibitors (contraindicated) 5
Partial enteral feeding is not a contraindication: Evidence shows ivabradine can be safely administered in patients not receiving full enteral feeds (58.8% in one pediatric series), though this is primarily adult data 6.
Monitoring Requirements
- Heart rate monitoring: Check resting heart rate at 2 weeks, then regularly during titration 2
- Cardiac rhythm: Monitor regularly for atrial fibrillation development 1
- Blood pressure: Ivabradine has no direct effect on blood pressure, making it well-tolerated in patients unable to tolerate beta-blocker titration 4
- Renal function: No direct effect on renal function 4
Special Populations
Older adults: Well tolerated when initiated at 2.5 mg twice daily 4. The lower starting dose accounts for increased risk of bradycardia and conduction abnormalities in this population.
Hepatic impairment: Avoid in advanced liver disease 4. No dose adjustment needed for mild-moderate impairment, but use with caution.